{"id":"NCT00413218","sponsor":"Astellas Pharma Inc","briefTitle":"Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections","officialTitle":"A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-03-08","primaryCompletion":"2015-03-03","completion":"2015-03-03","firstPosted":"2006-12-19","resultsPosted":"2017-08-01","lastUpdate":"2024-12-10"},"enrollment":450,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Candidiasis, Invasive","Candidemia","Mycoses"],"interventions":[{"type":"DRUG","name":"Isavuconazole","otherNames":["ASP9766","BAL8557"]},{"type":"DRUG","name":"Caspofungin","otherNames":["Cancidas"]},{"type":"DRUG","name":"Voriconazole","otherNames":["VFend"]}],"arms":[{"label":"Isavuconazole (ISA)","type":"EXPERIMENTAL"},{"label":"Caspofungin (CAS)/Voriconazole","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to compare the safety and efficacy of isavuconazole versus caspofungin followed by voriconazole in the treatment of candidemia and other invasive Candida infections.","primaryOutcome":{"measure":"Percentage of Participants With Overall Response of Success at the End of Intravenous Therapy (EOIV) as Determined by the Data Review Committee (DRC) Based on the Assessments of Clinical and Mycological Responses as Well as Alternative Systemic AFT Use","timeFrame":"End of Intravenous Treatment (EOIV) (Days 11-56)","effectByArm":[{"arm":"Isavuconazole (ISA)","deltaMin":60.3,"sd":null},{"arm":"Caspofungin (CAS)/Voriconazole","deltaMin":71.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":113,"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","China","France","Germany","Hungary","India","Israel","Italy","Lebanon","Malaysia","Mexico","New Zealand","Philippines","Russia","Singapore","South Africa","Spain","Switzerland","Thailand"]},"refs":{"pmids":["30289478","25902926"],"seeAlso":["https://astellasclinicalstudyresults.com/study.aspx?ID=295"]},"adverseEventsSummary":{"seriousAny":{"events":112,"n":220},"commonTop":["Hypokalaemia","Pyrexia","Diarrhoea","Vomiting","Constipation"]}}